PMID- 35399233
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2072-1439 (Print)
IS  - 2077-6624 (Electronic)
IS  - 2072-1439 (Linking)
VI  - 14
IP  - 3
DP  - 2022 Mar
TI  - Comprehensive analysis of aneuploidy status and its effect on the efficacy of 
      EGFR-TKIs in lung cancer.
PG  - 625-634
LID - 10.21037/jtd-22-73 [doi]
AB  - BACKGROUND: Lung cancer has the highest mortality rate among cancers worldwide, 
      and most patients are diagnosed with non-small-cell lung cancer (NSCLC), and 
      evaluating the clinical efficacy of molecularly targeted cancer therapy remains a 
      major challenge. METHODS: This paper retrospectively investigated the outcome 
      information of 291 lung cancer patients detected by next-generation sequencing 
      (NGS) analysis and fluorescence in situ hybridization (FISH), including 63 
      patients with lung cancer who were followed up. We analyzed epidermal growth 
      factor receptor (EGFR) mutation abundance and aneuploidy status to evaluate 
      clinical efficacy. RESULTS: The progress free survival (PFS) of patients 
      diagnosed as euploidy was actually higher than that of patients diagnosed with 
      aneuploidy, and was related to both the objective response rate (ORR) and disease 
      control rate (DCR). Patients with an epidermal growth factor receptor (EGFR) 
      mutation abundance >/=28.86% had slightly higher ORR and similar DCR. Two-way 
      analysis of variance was used to assess the effects of EGFR mutation abundance 
      and tumor aneuploidy status on patients' PFS. The results indicated a strong 
      correlation between aneuploidy status and clinical efficacy, with euploid 
      patients having a higher ORR and DCR. CONCLUSIONS: Aneuploidy status could 
      effectively evaluate the clinical efficacy of patients with lung cancer. However, 
      EGFR mutations abundance could not predict the extent of benefit from tyrosine 
      kinase inhibitors (EGFR-TKI) treatment.
CI  - 2022 Journal of Thoracic Disease. All rights reserved.
FAU - Wei, Bing
AU  - Wei B
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Zhao, Chengzhi
AU  - Zhao C
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Yang, Ke
AU  - Yang K
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Yan, Chi
AU  - Yan C
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Chang, Yuxi
AU  - Chang Y
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Gao, Huijie
AU  - Gao H
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Guo, Yongjun
AU  - Guo Y
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
FAU - Ma, Jie
AU  - Ma J
AD  - Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
AD  - Henan Provincial Key Laboratory of Molecular Pathology, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Thorac Dis
JT  - Journal of thoracic disease
JID - 101533916
PMC - PMC8987823
OTO - NOTNLM
OT  - Aneuploidy, lung cancer
OT  - Next-generation sequencing (NGS)
OT  - epidermal growth factor receptor mutations abundance (EGFR mutations abundance)
OT  - fluorescence in situ hybridization (FISH)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jtd.amegroups.com/article/view/10.21037/jtd-22-73/coif). All authors 
      report that this work received technical support from Shanghai Tongshu 
      Biotechnology Co. Ltd. The authors have no other conflicts of interest to 
      declare.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/03/01
CRDT- 2022/04/11 05:11
PHST- 2021/12/17 00:00 [received]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/04/11 05:11 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - jtd-14-03-625 [pii]
AID - 10.21037/jtd-22-73 [doi]
PST - ppublish
SO  - J Thorac Dis. 2022 Mar;14(3):625-634. doi: 10.21037/jtd-22-73.